*You must be registered for the ANA2021 Virtual Annual Meeting to access the live SIG Series sessions.
Date/Time ET: Wednesday, November 3, 2021 - 11:30 AM – 1:00 PM
Description: Autoimmune neurology encompasses the diagnosis and treatment of neurological disorders with an autoimmune basis. These disorders can affect diverse areas of the immune system and produced severe but treatable disorders. This SIG will cover novel research into underlying disease mechanisms, diagnosis and treatments.
Chair: Anusha Yeshokumar, MD, Icahn School of Medicine at Mount Sinai
Co-Chair: Claude Steriade, MD, MSCI, New York University, Langone Health
- Describe candidate biomarkers of neurodegeneration in patients with autoimmune encephalitis
- Recognize the complementary role of inflammatory biomarkers in the diagnosis and follow-up of patients with autoimmune encephalitis
- Describe the approach currently used in the design of animal models for autoimmune encephalitis and how they may be used in the examination of clinically-relevant questions
CSF Biomarkers in Autoimmune Encephalitis
Gregory Day, MD, MSc, MSCI
Clinical Outcomes Following Status Epilepticus in Anti-nmdar Encephalitis
Seon-Jae Ahn, MD
Seoul National University Hospital
Genomic and Transcriptomic-wide Analysis Identifies Novel Genetic Risk Loci and Prioritization of Therapies for Myasthenia Gravis
Ruth Chia, PhD
National Institutes on Aging, National Institutes of Health
High Frequency of Asymptomatic Optic Nerve Enhancement in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
Shailee Shah, MD
Animal Models of Autoimmune Encephalitis
Jenny Linnoila, MD, PhD
Massachusetts General Hospital, Harvard Medical School
Continuing Medical Education
The American Neurological Association hosts a wide range of educational programs. These programs seek to enhance the development and success of those pursuing a career in academic neurology at all levels. There are educational offerings to benefit those at the beginning stages of their careers, including students and those in their first faculty position, as well as those looking for best practices in Chair level positions. These programs seek to enhance attendee success in the field of academic neurology and to contribute to the overall education of neurologists and neuroscientists.
The Special Interest Groups offer CME to eligible participants. Click here to see a complete breakdown of how many credits are available per session.
ACCME Accreditation, AMA Designation, and MIPS Statements **Pertaining to Each Session Awarding CME**
The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Neurological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Instructions For Obtaining CME
Following the event, the evaluation and credit claiming system will open in OnDEC. Please complete the online evaluation by 12/31/2021 to obtain CME credit. You will be provided with a certificate after completing the evaluation. If you have any questions, please contact the ANA Meeting Coordinator at: email@example.com.
Click here to see a complete breakdown of how many credits are available per session.
Financial Disclosure Statements
The planners and faculty for this activity do not have any relationships to disclose unless listed here. Any relevant relationships with ACCME-defined ineligible companies will be mitigated according to ACCME Standards prior to the start of the activity.
Disclosure of Commercial Support
ANA received educational grants from the following ACCME-defined ineligible companies to support the CME aspects of this event: Added as confirmed.
DISCLAIMER: The ANA does not endorse or affiliate with third-party companies, products or services including those that may have elected to support the Special Interest Groups.